<DOC>
	<DOCNO>NCT00765921</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability anti-VEGF ( vascular endothelial cell growth factor ) treatment , ranibizumab , combination proton beam irradiation treatment choroidal melanoma determine incidence severity ocular adverse event . Systemic adverse event also evaluate . A secondary objective ass efficacy ranibizumab reduce ocular complication occur irradiation .</brief_summary>
	<brief_title>Ranibizumab Combination With Proton Beam Irradiation Choroidal Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients newly diagnose choroidal melanoma undergo proton therapy Tumors &gt; 15 mm large diameter and/or &gt; 5 mm height Tumors ≤ 15 mm large diameter ≤ 5 mm height locate ≤ 3 mm optic disc and/or macula , bestcorrected visual acuity 20/100 good study eye History prior treatment choroidal melanoma Pregnancy lactation Presence diabetic retinopathy History retinal vascular occlusion retinal vascular disease Active ocular inflammation history uveitis either eye History uncontrolled glaucoma ( defined intraocular pressure &gt; 30mmHg despite treatment antiglaucoma medication ) filtering surgery study eye Previous intravitreal injection Avastin® study eye nonstudy eye within 30 day . Concurrent use systemic antiVEGF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>glaucoma , neovascular</keyword>
	<keyword>macular edema</keyword>
	<keyword>eye enucleation</keyword>
	<keyword>antibody , monoclonal</keyword>
	<keyword>radiation oncology</keyword>
</DOC>